(0.15%) 5 316.36 points
(0.18%) 39 981 points
(0.12%) 16 762 points
(0.56%) $79.07
(3.02%) $2.49
(-0.33%) $2 387.10
(0.74%) $29.95
(-0.31%) $1 066.80
(0.13%) $0.920
(0.29%) $10.70
(0.08%) $0.789
(0.25%) $90.91
Live Chart Being Loaded With Signals
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering...
Stats | |
---|---|
Today's Volume | 807 466 |
Average Volume | 2.45M |
Market Cap | 17.40M |
EPS | $0 ( 2024-05-13 ) |
Next earnings date | ( $-0.390 ) 2024-05-22 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0300 |
ATR14 | $0.00100 (0.55%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-27 | Lederman Seth | Buy | 1 309 911 | Stock Option |
2024-02-27 | Lederman Seth | Buy | 1 903 680 | Stock Option |
2024-02-27 | Lederman Seth | Buy | 1 309 911 | Stock Option |
2024-02-27 | Lederman Seth | Buy | 235 320 | Stock Option |
2024-02-27 | Saenger Bradley | Buy | 282 000 | Stock Option |
INSIDER POWER |
---|
99.07 |
Last 97 transactions |
Buy: 77 144 979 | Sell: 389 187 |
Volume Correlation
Tonix Pharmaceuticals Correlation
10 Most Positive Correlations | |
---|---|
DYNT | 0.931 |
PXLW | 0.929 |
ATNX | 0.923 |
DSKE | 0.917 |
FTFT | 0.914 |
PRDS | 0.906 |
LIVE | 0.906 |
CIGI | 0.904 |
DGLY | 0.9 |
BYFC | 0.9 |
10 Most Negative Correlations | |
---|---|
JNCE | -0.88 |
UEIC | -0.872 |
UIHC | -0.872 |
QRHC | -0.862 |
HPLTU | -0.86 |
CENX | -0.856 |
EML | -0.854 |
GRPH | -0.852 |
BNIXU | -0.85 |
PWFL | -0.848 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Tonix Pharmaceuticals Correlation - Currency/Commodity
Tonix Pharmaceuticals Financials
Annual | 2023 |
Revenue: | $7.77M |
Gross Profit: | $-1.26M (-16.27 %) |
EPS: | $-6.85 |
FY | 2023 |
Revenue: | $7.77M |
Gross Profit: | $-1.26M (-16.27 %) |
EPS: | $-6.85 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $-112.09M (0.00 %) |
EPS: | $-20.11 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-0.976 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators